These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30146959)

  • 61. Designing a Delinked Incentive for Critical Antibiotics: Lessons from Norway.
    Årdal C; Johnsen J; Johansen K
    J Law Med Ethics; 2018 Jun; 46(1_suppl):43-49. PubMed ID: 30146956
    [TBL] [Abstract][Full Text] [Related]  

  • 62. (Inter)nationalising the antibiotic research and development pipeline.
    Singer AC; Kirchhelle C; Roberts AP
    Lancet Infect Dis; 2020 Feb; 20(2):e54-e62. PubMed ID: 31753765
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The Wrong Cure: Financial Incentives for Unimpressive New Antibiotics.
    Sinha MS; Powers JH; Kesselheim AS
    J Infect Dis; 2021 May; 223(9):1506-1509. PubMed ID: 32827433
    [No Abstract]   [Full Text] [Related]  

  • 64. Funding: Donor drugs.
    Willyard C
    Nature; 2016 May; 533(7601):S43-5. PubMed ID: 27144609
    [No Abstract]   [Full Text] [Related]  

  • 65. Incentives aim to boost antibiotic development.
    Roberts JP
    Nat Biotechnol; 2012 Aug; 30(8):735. PubMed ID: 22871701
    [No Abstract]   [Full Text] [Related]  

  • 66. Effective antibacterials: at what cost? The economics of antibacterial resistance and its control.
    White AR;
    J Antimicrob Chemother; 2011 Sep; 66(9):1948-53. PubMed ID: 21700625
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The Global Innovation Model for Antibiotics Needs Reinvention.
    Balasegaram M; Clift C; Røttingen JA
    J Law Med Ethics; 2015; 43 Suppl 3():22-6. PubMed ID: 26243239
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Challenges and solutions for clinical development of new antibacterial agents: results of a survey among pharmaceutical industry professionals.
    Bettiol E; Wetherington JD; Schmitt N; Harbarth S;
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3695-9. PubMed ID: 25918147
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Realigning incentives for developing and pricing new anticancer treatments.
    Howard DH
    JAMA; 2011 Jun; 305(22):2347-8. PubMed ID: 21642689
    [No Abstract]   [Full Text] [Related]  

  • 70. Use of and microbial resistance to antibiotics in China: a path to reducing antimicrobial resistance.
    Cui D; Liu X; Hawkey P; Li H; Wang Q; Mao Z; Sun J
    J Int Med Res; 2017 Dec; 45(6):1768-1778. PubMed ID: 29239248
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Economics of Public Antibiotics Development.
    Okhravi C
    Front Public Health; 2020; 8():161. PubMed ID: 32509716
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Antibiotic innovation for future public health needs.
    Theuretzbacher U
    Clin Microbiol Infect; 2017 Oct; 23(10):713-717. PubMed ID: 28652114
    [TBL] [Abstract][Full Text] [Related]  

  • 73. ReRouting biomedical innovation: observations from a mapping of the alternative research and development (R&D) landscape.
    Greenberg A; Kiddell-Monroe R
    Global Health; 2016 Sep; 12(1):54. PubMed ID: 27627882
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The drug-resistant bacteria that pose the greatest health threats.
    Willyard C
    Nature; 2017 Feb; 543(7643):15. PubMed ID: 28252092
    [No Abstract]   [Full Text] [Related]  

  • 75. Responsible use of negative research outcomes-accelerating the discovery and development of new antibiotics.
    Yu H
    J Antibiot (Tokyo); 2021 Sep; 74(9):543-546. PubMed ID: 34272495
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Discovery and development of new antibacterial drugs: learning from experience?
    Jackson N; Czaplewski L; Piddock LJV
    J Antimicrob Chemother; 2018 Jun; 73(6):1452-1459. PubMed ID: 29438542
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Outlook: the profit problem in antibiotic R&D.
    Nathan C; Goldberg FM
    Nat Rev Drug Discov; 2005 Nov; 4(11):887-91. PubMed ID: 16247440
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Resistance to antibiotics: are we in the post-antibiotic era?
    Alanis AJ
    Arch Med Res; 2005; 36(6):697-705. PubMed ID: 16216651
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Antibiotic cycling and marketing into the 21st century: a perspective from the pharmaceutical industry.
    Lavin BS
    Infect Control Hosp Epidemiol; 2000 Jan; 21(1 Suppl):S32-5. PubMed ID: 10654633
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The ethics of setting national antibiotic policies using financial incentives.
    Li G; Hooper C; Papanikitas A; Hopkins S; Sharland M
    Br J Gen Pract; 2017 Sep; 67(662):419-420. PubMed ID: 28860299
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.